Astellas-UCB rheumatoid arthritis therapy wins marketing approval in Japan
The Japanese Ministry of Health, Labor and Welfare has approved Cimzia as a 200mg syringe for subcutaneous (s.c.) injection to treat adult RA patients who failed to respond
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.